Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
2002 1
2003 4
2004 1
2005 3
2006 3
2007 2
2008 2
2009 4
2010 2
2011 4
2012 5
2014 4
2015 4
2016 4
2017 4
2018 5
2019 7
2020 7
2021 9
2022 3
2023 2
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

71 results

Results by year

Filters applied: . Clear all
Page 1
Prevention and Treatment of Cancer-Related Infections, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology.
Baden LR, Swaminathan S, Angarone M, Blouin G, Camins BC, Casper C, Cooper B, Dubberke ER, Engemann AM, Freifeld AG, Greene JN, Ito JI, Kaul DR, Lustberg ME, Montoya JG, Rolston K, Satyanarayana G, Segal B, Seo SK, Shoham S, Taplitz R, Topal J, Wilson JW, Hoffmann KG, Smith C. Baden LR, et al. Among authors: cooper b. J Natl Compr Canc Netw. 2016 Jul;14(7):882-913. doi: 10.6004/jnccn.2016.0093. J Natl Compr Canc Netw. 2016. PMID: 27407129
Gilteritinib in Combination With Induction and Consolidation Chemotherapy and as Maintenance Therapy: A Phase IB Study in Patients With Newly Diagnosed AML.
Pratz KW, Cherry M, Altman JK, Cooper BW, Podoltsev NA, Cruz JC, Lin TL, Schiller GJ, Jurcic JG, Asch A, Wu R, Hill JE, Gill SC, James AJ, Rich ES, Hasabou N, Perl AE, Levis MJ. Pratz KW, et al. Among authors: cooper bw. J Clin Oncol. 2023 Sep 10;41(26):4236-4246. doi: 10.1200/JCO.22.02721. Epub 2023 Jun 28. J Clin Oncol. 2023. PMID: 37379495 Clinical Trial.
A multicenter study of posttransplantation low-dose inotuzumab ozogamicin to prevent relapse of acute lymphoblastic leukemia.
Metheny LL, Sobecks R, Cho C, Fu P, Margevicius S, Wang J, Ciarrone L, Kopp S, Convents RD, Majhail N, Caimi PF, Otegbeye F, Cooper BW, Gallogly M, Malek E, Tomlinson B, Gerds AT, Hamilton B, Giralt S, Perales MA, de Lima M. Metheny LL, et al. Among authors: cooper bw. Blood Adv. 2024 Mar 26;8(6):1384-1391. doi: 10.1182/bloodadvances.2023011514. Blood Adv. 2024. PMID: 38170741 Free PMC article.
History of drug use in allogeneic hematopoietic cell transplant recipients.
Abou-Ismail MY, Ravi G, Fu P, Cao S, Vuyyala S, Caimi P, Kolk M, Ferrari N, Boughan K, Cooper B, Gallogly M, Otegbeye F, Tomlinson B, de Lima M, Metheny L. Abou-Ismail MY, et al. Among authors: cooper b. Bone Marrow Transplant. 2021 Mar;56(3):581-585. doi: 10.1038/s41409-020-01058-z. Epub 2020 Sep 17. Bone Marrow Transplant. 2021. PMID: 32943757
Flow cytometry of DNMT1 as a biomarker of hypomethylating therapies.
Woost PG, William BM, Cooper BW, Ueda Oshima M, Otegbeye F, De Lima MJ, Wald D, Mahfouz RZ, Saunthararajah Y, Stefan T, Jacobberger JW. Woost PG, et al. Among authors: cooper bw. Cytometry B Clin Cytom. 2024 Jan;106(1):11-24. doi: 10.1002/cyto.b.22158. Epub 2024 Feb 12. Cytometry B Clin Cytom. 2024. PMID: 38345160
Targeted Marrow Irradiation Intensification of Reduced-Intensity Fludarabine/Busulfan Conditioning for Allogeneic Hematopoietic Stem Cell Transplantation.
Ali N, Sharma AA, de Rezende ACP, Otegbeye F, Latif BM, Kerbauy MN, Cooper BW, Sanchez G, Metheny L, Bal SK, Sakuraba R, Tomlinson BK, Boughan KM, Kerbauy L, Malek E, Ribeiro AF, Gallogly M, Mansur D, Pereira G, Weltman E, Sekaly RP, de Lima M, Caimi PF, Hamerschlak N. Ali N, et al. Among authors: cooper bw. Transplant Cell Ther. 2022 Jul;28(7):370.e1-370.e10. doi: 10.1016/j.jtct.2022.04.001. Epub 2022 Apr 11. Transplant Cell Ther. 2022. PMID: 35421620 Free article. Clinical Trial.
A Phase I Study to Determine the Maximum Tolerated Dose of ex Vivo Expanded Natural Killer Cells Derived from Unrelated, HLA-Disparate Adult Donors.
Otegbeye F, Cooper B, Caimi P, Zamborsky K, Reese-Koc J, Hillian A, Hernandez-Collazo Y, Lee G, Boughan K, Tomlinson B, Gallogly M, Metheny L, Bajor D, Selfridge J, Saltzman J, Lazarus H, de Lima M, Wald D. Otegbeye F, et al. Among authors: cooper b. Transplant Cell Ther. 2022 May;28(5):250.e1-250.e8. doi: 10.1016/j.jtct.2022.02.008. Epub 2022 Feb 14. Transplant Cell Ther. 2022. PMID: 35172204 Free PMC article. Clinical Trial.
71 results